Avista Pharma acquisition finalized
LONGMONT — The acquisition of Avista Pharma Solutions Inc., a pharmaceutical ingredient manufacturing company with a major Longmont presence, by Cambrex Corp. (NYSE: CBM) closed this week.
As a result of the $252-million deal, first announced in November, New Jersey-based Cambrex, a generic active pharmaceutical ingredient maker, has strengthened its position as a fully integrated small molecule contract development and manufacturing organization across the drug lifecycle, according to a company news release.
“Acquiring Avista adds a full complement of early-stage development capabilities to Cambrex’s larger scale capabilities for both APIs and finished dosage forms,” Cambrex CEO Steve Klosk said in a prepared statement. “We are excited to start off 2019 integrating Avista into Cambrex’s global network of facilities.”
SPONSORED CONTENT
Federal District Court Rules Corporate Transparency Act Unconstitutional . . . But Most Small Businesses Must Still Comply
Lyons Gaddis Real Estate and Business Attorney Cameron Grant shares important details of the Corporate Transparency Act (CTA).
LONGMONT — The acquisition of Avista Pharma Solutions Inc., a pharmaceutical ingredient manufacturing company with a major Longmont presence, by Cambrex Corp. (NYSE: CBM) closed this week.
As a result of the $252-million deal, first announced in November, New Jersey-based Cambrex, a generic active pharmaceutical ingredient maker, has strengthened its position as a fully integrated small molecule contract development and manufacturing organization across the drug lifecycle, according to a company news release.
“Acquiring Avista adds a full complement of early-stage development capabilities to Cambrex’s larger scale capabilities for both…
THIS ARTICLE IS FOR SUBSCRIBERS ONLY
Continue reading for less than $3 per week!
Get a month of award-winning local business news, trends and insights
Access award-winning content today!
